| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-05-23 |
LogicBio Therapeutics (USA - MA) |
chief scientific officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-16 |
Fate Therapeutics (USA - CA) Memorial Sloan Kettering Cancer (USA - NY) |
chimeric antigen receptor (CAR) constructs , off-the-shelf T-cell immunotherapies |
|
R&D - research |
Cancer - Oncology - Immunological diseases |
R&D agreement |
| 2018-05-15 |
Horama (France) |
chairman of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
| 2018-05-15 |
Five Prime Therapeutics (USA - CA) |
chief scientific officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-05-15 |
Lysogene (France) |
chief scientific officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-11 |
Intralytix (USA - MA) |
|
|
construction of new premises |
Infectious diseases |
Construction of new premises |
| 2018-05-08 |
Audentes Therapeutics (USA - CA) |
president and chief executive officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-08 |
TC BioPharm (UK) Scotia Biologics (UK) |
proprietary tumour-specific antibodies for TCB’s CAR-T platform |
|
development |
Cancer - Oncology - Infectious diseases |
Development agreement |
| 2018-05-07 |
HTG Molecular Diagnostics (USA - AZ) Firalis (France) |
next?generation sequencing (NGS)?based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti?TNF? therapy |
rheumatoid arthritis |
licensing, commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
Commercialisation agreement |
| 2018-05-07 |
Pfizer (USA - NY) Wave LIfe Sciences (USA - MA) |
nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases |
metabolic hepatic diseases, such as nonalcoholic steatohepatitis |
research - development - R&D - licensing |
Liver diseases - Hepatic diseases |
Milestone |
| 2018-05-03 |
Sarepta Therapeutics (USA - MA) Myonexus Therapeutics (USA - MA) |
MYO-101 |
Limb-girdle muscular dystrophy (LGMD) |
development |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Development agreement |
| 2018-05-03 |
Sangamo Therapeutics (USA - CA) |
chief business officer |
|
resignation |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-03 |
Sangamo Therapeutics (USA - CA) |
chief technology officer |
|
nomination |
|
Nomination |
| 2018-05-02 |
Iontas (UK) aTen Therapeutics (UK) |
- antibodies against biological targets selected by aTen.
|
|
|
Cancer - Oncology |
Collaboration agreement |
| 2018-05-02 |
LogicBio Therapeutics (USA - MA) |
chief operating officer - senior director of manufacturing |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-01 |
BeiGene (China) |
general manager and president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-04-30 |
Glythera (UK) |
member of the scientific advisory board |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-04-25 |
Syntimmune (USA - MA) |
member of the board of directors |
|
nomination |
Autoimmune diseases |
Nomination |
| 2018-04-24 |
Orchard Therapeutics (UK) |
new corporate office in Boston |
|
opening of new premises |
Rare diseases - Genetic diseases |
Opening of new premises |
| 2018-04-24 |
Lysogene (France) SATT Conectus (France) IGBMC (France) |
gene therapy |
fragile X syndrome |
research - collaboration |
Rare diseases - Genetic diseases |
Research agreement |
